Seeing further.


We’re advancing our RNA-based treatments so patients with cancers and rare diseases can enjoy the moments that matter.

Learn More

Transforming Immunity. Restoring Hope.

We’re committed to redefining the treatment of certain cancers and rare diseases.

Learn More

Scientists. Believers. People.

At Idera, we’re working hard to translate our nucleic acid science into life-changing medicines.

Discover Idera

The Latest

Keep up with what’s happening at Idera Pharmaceuticals.


U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals’ IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma

Phase 3 Trial Initiation Planned for First Quarter 2018 CAMBRIDGE, Mass. and EXTON, Pa. , Nov. 29,… Read more 

Idera to Present at the 29th Annual Piper Jaffray Healthcare Conference

CAMBRIDGE, Mass. and EXTON, Pa. , Nov. 27, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc.… Read more 

Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC)

- Available Translational Data Continue to Demonstrate Correlation between Proliferation and… Read more 

Learn More


Idera Pharmaceuticals, Inc. Events

Idera Pharmaceuticals, Inc. Events… Read more 

Learn More